Table 5.
Dabigatran pharmacokinetics after single doses of dabigatran etexilate 150 mg and 600 mg
| Parameter | Non-compartmental parameters of free non-conjugated dabigatran | Non-compartmental parameters of total dabigatran (free and conjugated) | ||||||
|---|---|---|---|---|---|---|---|---|
| Dabigatran etexilate 150 mg (n = 40) | Dabigatran etexilate 600 mg (n = 40) | Dabigatran etexilate 150 mg (n = 40) | Dabigatran etexilate 600 mg (n = 40) | |||||
| gMean | gCV (%) | gMean | gCV (%) | gMean | gCV (%) | gMean | gCV (%) | |
| AUC∞ (ng·h/mL) | 540 | 74.3 | 2,230 | 43.5 | 703 | 71.5 | 3,070 | 42.1 |
| Cmax (ng/mL) | 71.4 | 80.8 | 281 | 38.5 | 87.8 | 76.8 | 383 | 38.1 |
| tmax (h)a | 2.03 | 0.983–3.15 | 3.00 | 1.50–6.03 | 2.03 | 1.48–3.15 | 3.00 | 1.50–6.03 |
AUC ∞ area under the plasma concentration-time curve from time zero to infinity, C max maximum observed plasma concentration, gCV geometric coefficient of variation, gMean geometric mean, t max time to reach Cmax
aFor tmax, the median and range (min to max) are given